Lupin inks pact to distribute Eli Lilly's diabetes injection in India
New Delhi: Drug major Lupin has recently announced a partnership with Eli Lilly and Company (India) to distribute Eli Lilly's diabetes injection Aplevant in the country. Lupin said the expansion of the business partnership with Eli Lilly is aimed at widening access to diabetes medicines in India.
Under the new partnership, Lupin will distribute and market Lilly's Aplevant (dulaglutide), once a weekly injection for type 2 diabetes treatment, Lupin said in a regulatory filing.
Lupin expects to make Aplevant available in India from October 2018, it said in a statement.
The partnership between the two companies was initiated in 2011 to expand the promotion and distribution of Lilly's diabetes portfolio in India where Lupin has a large network.
"With this new partnership, we are expanding our diabetes portfolio to include a once-weekly diabetes treatment, and improving access to innovative medications for better diabetic care in India," Rajeev Sibal, Lupin President - India Region Formulations, said.
Read Also: Lupin to add GLP 1 analog to its diabetes portfolio in India
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd